Literature DB >> 1373598

Infants at risk for schizophrenia: sequelae of a genetic neurointegrative defect. A review and replication analysis of pandysmaturation in the Jerusalem Infant Development Study.

B Fish1, J Marcus, S L Hans, J G Auerbach, S Perdue.   

Abstract

A 1975 report stated that a schizophrenic genotype may be manifested in infants by a neurointegrative defect called pandysmaturation. Recent evidence supports this: (1) 12 studies found delayed development in schizophrenics' infants and in preschizophrenics; (2) "blind" psychometric evaluations favored an adult schizotypal disorder in four to six of seven high-risk subjects with pandysmaturation in the New York study; and (3) finally, in a partial replication of this method using the Jerusalem data, blind diagnoses of "probable" and "possible" pandysmaturation were significantly related to a parental diagnosis of schizophrenia and to cognitive and motor neurointegrative deficits at 10 years. Obstetrical complications were unrelated to diagnosis, pandysmaturation, or outcome in the overall sample. However, we found a small subgroup of schizophrenic offspring in whom the most severe motor deficits at follow-up were related to obstetrical complications, pandysmaturation, and low birth weight.

Entities:  

Mesh:

Year:  1992        PMID: 1373598     DOI: 10.1001/archpsyc.1992.01820030053007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  59 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

2.  Premorbid multivariate markers of neurodevelopmental instability in the prediction of adult schizophrenia-spectrum disorder: a high-risk prospective investigation.

Authors:  Shana Golembo-Smith; Jason Schiffman; Emily Kline; Holger J Sørensen; Erik L Mortensen; Laura Stapleton; Kentaro Hayashi; Niels M Michelsen; Morten Ekstrøm; Sarnoff Mednick
Journal:  Schizophr Res       Date:  2012-06-02       Impact factor: 4.939

3.  Gene-environment interactions in mental disorders.

Authors:  Ming T Tsuang; Jessica L Bar; William S Stone; Stephen V Faraone
Journal:  World Psychiatry       Date:  2004-06       Impact factor: 49.548

Review 4.  Approaches for adolescents with an affected family member with schizophrenia.

Authors:  Vaibhav A Diwadkar; Konasale M Prasad; Matcheri S Keshavan
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 5.285

5.  Premorbid characterization in schizophrenia: the Pittsburgh High Risk Study.

Authors:  Matcheri S Keshavan; Vaibhav A Diwadkar; Debra M Montrose; Jeff A Stanley; Jay W Pettegrew
Journal:  World Psychiatry       Date:  2004-10       Impact factor: 49.548

Review 6.  Potential microbial origins of schizophrenia and their treatments.

Authors:  S Hossein Fatemi
Journal:  Drugs Today (Barc)       Date:  2009-04       Impact factor: 2.245

Review 7.  Perinatal Risks and Childhood Premorbid Indicators of Later Psychosis: Next Steps for Early Psychosocial Interventions.

Authors:  Cindy H Liu; Matcheri S Keshavan; Ed Tronick; Larry J Seidman
Journal:  Schizophr Bull       Date:  2015-04-22       Impact factor: 9.306

Review 8.  Viruses, schizophrenia, and bipolar disorder.

Authors:  R H Yolken; E F Torrey
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

9.  Enuresis as a premorbid developmental marker of schizophrenia.

Authors:  Thomas M Hyde; Amy Deep-Soboslay; Bianca Iglesias; Joseph H Callicott; James M Gold; Andreas Meyer-Lindenberg; Robyn A Honea; Llewellyn B Bigelow; Michael F Egan; Esther M Emsellem; Daniel R Weinberger
Journal:  Brain       Date:  2008-07-31       Impact factor: 13.501

10.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.

Authors:  Jeroen P F Koning; Diederik E Tenback; Jim van Os; André Aleman; René S Kahn; Peter N van Harten
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.